-- Deep Intelligent Pharma (DIP) has officially launched a groundbreaking generative AI platform that promises to redefine how the world develops medicine. Unveiled today at Microsoft Build 2025, where DIP was the exclusive presenter from Asia, the new solution represents a bold leap forward in the fusion of AI and life science innovation.
Built in partnership with Microsoft Azure O3, DIP’s next-gen platform harnesses multi-agent AI swarms capable of performing scientific writing, statistical reasoning, document validation, and regulatory compliance with superhuman scale and precision. It directly targets one of the most expensive, slow, and error-prone challenges in pharma: the creation of clinical and regulatory documents.
“This isn’t just an upgrade — it’s a reinvention of how life science companies operate,” said Xing Li, CEO of DIP. “We’ve turned months of expert labor into minutes of AI-driven intelligence — bringing speed, accuracy, and scientific depth into perfect alignment.”
A Paradigm Shift in Life Science R&D
The DIP platform is designed to eliminate the longstanding bottlenecks of pharmaceutical development:
- 90%+ reduction in documentation time
- 75% faster regulatory submissions
- Zero-defect document generation through statistical and methodological inference
- Seamless parsing of complex formats like tables, PDFs, and legacy data silos
- Real-time consistency checks across massive, multi-document workflows
Real Results, Real Impact
At Build, DIP showcased a live case study in which its AI-authored protocol for a novel cancer immunotherapy was approved by Japan’s PMDA with zero revisions — in a single review cycle. The message was clear: generative AI isn’t the future of pharma — it’s happening now.
With over 1,000 pharma clients, 20,000+ submission projects, and 5 billion words processed, DIP is already trusted by industry leaders across Asia and beyond. And now, it’s setting a new global standard for how data becomes discovery.
Transforming the Economics of Innovation
With drug development costs surpassing $2 billion per therapy and timelines stretching 10–15 years, DIP’s AI orchestration radically accelerates innovation — helping companies reinvest resources into science instead of paperwork.
“This is AI that thinks like a scientist, writes like a regulator, and moves at the speed of discovery,” added Shinya Yamamoto. “We’re not just helping companies go faster — we’re helping them aim higher.”
About Deep Intelligent Pharma
Founded in 2017, Deep Intelligent Pharma is a pioneering AI company with global offices in Japan, China, and Singapore. Its mission is to empower pharmaceutical and medtech innovators through intelligent automation, turning regulatory complexity into a catalyst for speed, scale, and scientific excellence. DIP has built agent swarms based on generative AI models with outcome based payment model in life science R&D.
Contact Info:
Name: Xing Li
Email: Send Email
Organization: Deep Intelligent Pharma
Website: https://x-doc.ai/
Release ID: 89160572
Should there be any problems, inaccuracies, or doubts arising from the content provided in this press release that require attention or if a press release needs to be taken down, we urge you to notify us immediately by contacting error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will promptly address your concerns within 8 hours, taking necessary steps to rectify identified issues or assist with the removal process. Providing accurate and dependable information is central to our commitment.
